Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asian randomized double-blind placebo-controlled study of mirogabalin for central neuropathic pain after spinal cord injury
KCT0004730Phase 4Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of mirogabalin in central neuropathic pain (CNP), sponsored by Daiichi Sankyo Co., Ltd.. Started Feb 2020; status: recruiting.
02
Drugs
mirogabalin
03
Conditions
central neuropathic pain (CNP)
Beyond the preview
Go deeper on KCT0004730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004730.